skip to main content

NTrans Technologies

Gene-editing therapy for Duchenne

NTrans Technologies (NTrans) is developing a gene-editing therapy for the muscle disease Duchenne (DMD). The patented therapeutic platform activates a cell's natural uptake mechanism to safely deliver gene-editing systems, such as CRIPR-Cas9, into a target cell, where it efficiently restores the function of the defective gene.
The Mibiton funding will be used to purchase advanced equipment to support the development process at NTrans.

Marco de Boer, former CEO

"Mibiton's support has enabled us to accelerate our innovative programmes with the aim of delivering breakthrough gene-editing therapies to patients."